Jump to Navigation

On July 9, 2002, the National Heart, Lung and Blood Institute ("NHLBI"), an agency of the federal government and part of the National Institutes of Health ("NIH"), halted a major clinical trial of the risks and benefits of hormone replacement therapy involving estrogen and progestin — the combination of hormones found in Prempro — in healthy post menopausal women. The 16,600 patient study was abruptly halted after researchers found the risks of taking Prempro outweighed its benefits.

Prempro, which has been prescribed to over 6 million US women, is the leading estrogen-progestin combination hormone replacement therapy drug. Adverse affects linked to Prempro include an increase in strokes, heart attacks, breast cancer, and cardiovascular disease, and a doubling of rates of blood clots. If you took Prempro and have any of these injuries, please obtain a Free Consultation by submitting our online form, or by calling 866-273-1941.

OFFICE LOCATION: 707 Grant Street, Suite 2500 | Pittsburgh, PA 15219 | Phone: 866-273-1941 | Fax: 412-281-4229 | Email Us | Get Directions